ArticleFrontiers in immunology2026
Efficacy of low dose of rituximab to treat systemic lupus erythematosus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare the efficacy and safety of low-dose rituximab (RTX, 100 mg/month) versus belimumab (BEL, 10 mg/kg), as a control, in the treatment of systemic lupus erythematosus (SLE). Methods: A retrospective analysis was conducted on 117 SLE patients who received low-dose RTX (n=51) or BEL (n=66) at Fujian Medical University Union Hospital between January 2020 and June 2023. Data on baseline characteristics, laboratory parameters (platelet count, creatinine, proteinuria, complement C3/C4, erythrocyte sedimentation rate (ESR)), disease activity (SLEDAI-2K), glucocorticoid dosage, concomitant immunosuppressant use, efficacy assessments, and adverse events were collected. Paired t-tests or Wilcoxon tests were used for within-group comparisons, and independent-sample t-tests or Mann-Whitney U tests for between-group comparisons. Results: No significant differences were observed between the two groups at baseline for SLEDAI-2K, glucocorticoid levels, or anti-dsDNA ( Conclusion: Low-dose RTX (100 mg/month) can be regarded as a treatment option for SLE, based on its comparable efficacy to BEL in improving disease activity, increasing platelet count, and ameliorating proteinuria. Although BEL shows greater advantages in reducing glucocorticoid dosage and improving hypercoagulability, the overall evidence supports low-dose RTX as an effective and safe alternative for SLE, with a favourable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.